Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The investigators developed an easy identification model to identify metabolic syndrome in
patients with schizophrenia or schizoaffective disorder who received treatment of clozapine,
olanzapine, or risperidone. The accuracy of the investigators' models showed well. In the
study, the investigators aim to (1) to examine whether the developed identification models
can be generalized to patients taking other antipsychotics or patients with other diagnoses;
(2) to develop an easy risk score and validate it; (3) to switch antipsychotics to
amisulpride or aripiprazole for those with metabolic syndrome, and compare the changes of
metabolic parameters including adiponectin, and analyze their association with genetic
variants, demography, and clinical variables; (4) to establish models using artificial neural
network and statistic method to predict metabolic response after a switch to amisulpride or
aripiprazole; (5) to investigate the effect of antipsychotics on adiponectin gene expression
and secretion during the differentiation process of 3T3L1 adipocytes.